Literature DB >> 3259535

Primary histiocytosis X of the parieto-occipital lobe.

B Eriksen1, J Janinis, D Variakojis, J Winter, E Russel, R Marder, M C DalCanto.   

Abstract

Immunohistochemical and ultrastructural evidence support the concept that histiocytosis X is the result of proliferation of pathological Langerhans' cells. Central nervous system involvement by histiocytosis X has been commonly described in multisystem disease and in association with lytic skull lesions. Unifocal brain involvement by histiocytosis X without concomitant osseous involvement is rare, with only 14 cases reported in the literature to date. Ten of these cases have involved the hypothalamus; the remaining four have involved the frontal lobe (two cases) and the temporal lobe (two cases). The fifth case of extrahypothalamic unifocal histiocytosis X, the first female case, and the first case with parieto-occipital lobe involvement, is reported. Pathology demonstrated infiltration of brain parenchyma by clusters of characteristic histiocytosis X cells with an admixture of morphologically related giant cells, eosinophils, and lymphocytes. Langerhans' granules were identified in the histiocytosis X cells by electron microscopy. Immunohistochemistry showed strong S-100 protein, HLA-DR, and T6 antigen positivity by the histiocytosis X cells. Therapy included complete surgical excision and postoperative radiation therapy for the incompletely excised lesion. Patients with unifocal extrahypothalamic histiocytosis X may have a better prognosis than patients with localized hypothalamic disease.

Entities:  

Mesh:

Year:  1988        PMID: 3259535     DOI: 10.1016/s0046-8177(88)80216-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  1 in total

1.  Solitary Langerhans cell histiocytosis of frontal lobe: a case report and literature review.

Authors:  Shanshan Cai; Sheng Zhang; Xueyong Liu; Yuanxiang Lin; Chunlin Wu; Yupeng Chen; Jianping Hu; Xingfu Wang
Journal:  Chin J Cancer Res       Date:  2014-04       Impact factor: 5.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.